Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: William Whitehead Jr. who wrote (637)	5/6/1999 11:18:00 AM
From: Angelo	Read Replies (1) \| Respond to of 2344

Never put all your eggs in one basket. You should know that. My believe is that biomira will be $200 per shares two years from now,but there is the possibility that some thing can go wrong and the stock might go to .50cents. Angelo

To: William Whitehead Jr. who wrote (637)	5/6/1999 11:39:00 AM
From: StockMiser	Respond to of 2344

I think it all really depends on media exposure. We all know that Dr. McPherson was interviewed by the NY Times - so the hope is that they run an article, most likely in conjunction with the conference. As for the bridging study...they did release material information last year for the "interim". So the hope is that the final release expands on that. The 2 stem cell replacement studies with Theratope could also be significant given all that recent negative info on the ineffectiveness of stem cell therapy with chemo. If you are long, the conf is just a blip on the way to much bigger things. We will rock soon enough :) SM

To: William Whitehead Jr. who wrote (637)	5/6/1999 4:37:00 PM
From: Jibacoa	Read Replies (1) \| Respond to of 2344

Whitey: I don't know what the market is expecting out of the ASCO conference in Atlanta a week from this Saturday. BIOM is just going to be mentioned in two papers to be presented, so that is not too much to expect. If the N.Y. Times comes out with an article on cancer vaccines, at it has been rumored, that is a dog with a different collar, since that could possibly make a big "run up". Just remember what happened with Entremed and the anti-angiogenesis stocks, little RGEN and not so little TCLN included. Remember also what BIOM's stock did with the article on Fortune last November, even though the buying frenzy lasted less than two hours. BIOM has said that they plan to take an early look at phase III results 24 months after the start. If the "start" was last November that means it is only 18 months left, and if the results come as expected, they are planning on asking the FDA for an EXPEDITE APPROVAL. That means they could start selling the vaccine while they were still continuing with the phase III on breast cancer. Of course if Theratope gets approved for breast cancer, the use for prostate, ovary and colon, could be coming pretty fast afterwards. Then there is the results of the "bridging study" on some 18 patients with the new more potent vaccine, the results of which are to be released this year. Again, don't worry and keep buying it on any dips. It seems to me it did pretty well today in spite the late sell off, taking in account NASDAQ dropped more than 60 points. Bernard